Please assess the completion status of the following clinical trial:

Trial Title: Effect of GSK1014802 on Electrical Hyperalgesia and Threshold Tracking in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male between 18 and 55 years of age inclusive.~* AST, ALT, alkaline phosphatase and bilirubin ≤ 1.5xULN~* Healthy as determined by a responsible and experienced physician.~* Male subjects must agree to use one of the contraception methods requested.~* Body weight greater than or equal to 50 kg, BMI ≤29.9kg/m2~* Capable of giving written informed consent.~* QTcB or QTcF \< 450 msec.~Exclusion Criteria:~* A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result.~* Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).~* A positive pre-study drug/alcohol screen.~* A positive test for HIV antibody.~* Heart block, bundle branch block, hemi-block, evidence of accessory cardiac conduction pathways, long pauses \>2 s or other cardiac conduction abnormalities or cardiac arrhythmias on 12-lead ECG or 24 h Holter at screening.~* History of regular excessive alcohol consumption within 6 months of the study.~* The subject has participated in a clinical trial and has received an investigational product within 90 days o fthe strat of this study.~* Exposure to more than four new chemical entities within 12 months prior to the first dosing day.~* Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication.~* History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.~* Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.~* Unwillingness or inability to follow the procedures outlined in the protocol.~* Subject is mentally or legally incapacitated.~* Subjects with a history or regular use of tobacco- or nicotine-containing products within 6 months prior to screening.~* Consumption of red wine, seville oranges, grapefruit or grapefruit juice and/or pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices from 7 days prior to the first dose of study medication.~* Average daily caffeine intake equivalent to \> 4 cups of coffee or \> 6 cups of tea.~* Current or past history of symptomatic orthostatic hypotension or history of vasovagal episode(s).~* Subjects with systolic blood pressure persistently above 140 mmHg and/or diastolic blood pressure persistently above 90 mmHg.~* History of known or suspected seizures, including infantile febrile, unexplained significant and recent loss of consciousness or history of significant head trauma with loss of consciousness or a family history (first degree relative) of epilepsy or seizures (fits).~* The subject has a history of chronic pain before screening.~* The subject has used any topical steroid in the previous 30 days if, in the opinion of the investigator this is likely to interfere with study assessments.~* The subject has used any topical capsaicin preparations on the forearms in the previous 30 days.~* The subject suffers from eczema, psoriasis or any other acute or chronic dermatological problem if, in the opinion of the investigator this is likely to interfere with study assessments~* The subject suffers from tinnitus, or has done in the past 3 months.~* Suffers from skin infection or inflammation of the forearm, or has other arm skin irregularities that may in the opinion of the investigator interfere with study assessments.~* Needle phobic.~* The subject does not produce an area of allodynia or hyperalgesia to the electrical hyperalgesia model during the screening session.~* The subject is unable to tolerate the electrical hyperalgesia model or threshold tracking, including anxiety or atypical response to the stimulation.~* Any history of suicidal behaviour or any suicidal ideation of type 4 or 5 on the C-SSRS in the last month.~* Poor veins that would be estimated not to be suitable by a physician for repeated cannulation in both arms.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Period 1 (Type: OTHER): None
- Period 2 (Type: OTHER): None
- Period 3 (Type: OTHER): None
- Period 4 (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues